[{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Private Placement","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subdermal Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Nano Precision Medical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Nano Precision Medical","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Nano Precision Medical"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Second Sight Medical Products","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Second Sight Medical Products","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Second Sight Medical Products"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Transdermal Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vivani Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The net proceeds from the private placement will used to support the clinical development of NPM-139 (semaglutide), which is being evaluated for the treatment of obesity.

Product Name : NPM-139

Product Type : Peptide

Upfront Cash : Undisclosed

March 27, 2025

Lead Product(s) : Semaglutide

Therapeutic Area : Nutrition and Weight Loss

Highest Development Status : Preclinical

Sponsor : Undisclosed

Deal Size : $8.2 million

Deal Type : Private Placement

blank

02

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with obesity and type-2 diabetes.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Inapplicable

December 19, 2024

Lead Product(s) : Exenatide

Therapeutic Area : Nutrition and Weight Loss

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Inapplicable

November 07, 2024

Lead Product(s) : Exenatide

Therapeutic Area : Nutrition and Weight Loss

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

04

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : NPM115 (exenatide) implant i is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Inapplicable

September 26, 2024

Lead Product(s) : Exenatide

Therapeutic Area : Nutrition and Weight Loss

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

05

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Inapplicable

June 13, 2024

Lead Product(s) : Exenatide

Therapeutic Area : Endocrinology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

06

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Inapplicable

April 09, 2024

Lead Product(s) : Exenatide

Therapeutic Area : Endocrinology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

07

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Inapplicable

February 28, 2024

Lead Product(s) : Exenatide

Therapeutic Area : Nutrition and Weight Loss

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

08

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : $55.0 million

August 30, 2022

Lead Product(s) : Exenatide

Therapeutic Area : Endocrinology

Highest Development Status : Preclinical

Sponsor : Second Sight Medical Products

Deal Size : Undisclosed

Deal Type : Merger

blank

09

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Nano Precision Medical, leveraging its proprietary NanoPortalTM drug implant technology, is creating a portfolio of new drugs including NPM’s lead program, NPM-119, that address medication non-adherence, a leading reason for poor clinical outcomes.

Product Name : NPM-115

Product Type : Peptide

Upfront Cash : Undisclosed

July 02, 2022

Lead Product(s) : Exenatide

Therapeutic Area : Endocrinology

Highest Development Status : Preclinical

Sponsor : Nano Precision Medical

Deal Size : Undisclosed

Deal Type : Merger

blank